Volume 19 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(3): 428-431
CHEN Shu, ZHENG Jing, LI Yan-hua. The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828
Citation: CHEN Shu, ZHENG Jing, LI Yan-hua. The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828
shu

The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer

doi: 10.16766/j.cnki.issn.1674-4152.001828

  • Department of Gynecologic Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0384

  • Received Date: 2020-10-15
    Available Online: 2022-02-19
    Abstract
  •   Objective  To analyze the expression of CD24 and Siglec-10 in different ovarian tissues, and to explore their expression and significance in epithelial ovarian cancer.  Methods  The expression of CD24 and Siglec-10 were detected by immunohistochemistry (SP), their expression and characteristics in different ovarian tissues were analyzed. The relationship between CD24, Siglec-10 and different pathological parameters of epithelial ovarian cancer and the relationship between the two parameters were investigated, and the relationship between CD24, Siglec-10 and the occurrence, development, invasion, metastasis and recurrence of epithelial ovarian cancer were explored.  Results  CD24 and Siglec-10 were not expressed in normal ovarian tissues, and their expression levels increased with the benign, borderline, and malignant changes of ovarian tumors, the difference between the groups was statistically significant (P < 0.05). The expression level of CD24 and Siglec-10 was closely related to FIGO staging, lymph node metastasis, omental metastasis, pelvic and abdominal implantation, and recurrence, the difference was statistically significant (P < 0.05). The highly expression level of CD24 and Siglec-10 had a significant correlation in epithelial ovarian cancer (r=0.500, P < 0.001).  Conclusion  CD24 and Siglec-10 have a synergistic effect, which can jointly promote the occurrence and development, invasion, metastasis and recurrence of tumors. CD24-Siglec-10 is expected to become a new immune detection point, providing more possibilities for the immunotherapy of epithelial ovarian cancer.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
    [2]
    EISENHAUER E A. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 1161-1165. http://www.ncbi.nlm.nih.gov/pubmed/28574933
    [3]
    PIGNATA S, CECERE C S, BOIS A D, et al. Treatment of recurrent ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 51-56.
    [4]
    MORGAN R J, ARMSTRONG D K, ALVAREZ R D, et al. Ovarian cancer, Version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163. doi: 10.6004/jnccn.2016.0122
    [5]
    TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
    [6]
    HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018, 319(6): 595-606. doi: 10.1001/jama.2017.21421
    [7]
    DUEX J E, OWENS C, CHAUCA-DIAZ A, et al. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis[J]. Cancer Res, 2017, 77(18): 4858-4867. doi: 10.1158/0008-5472.CAN-17-0367
    [8]
    BARKAL A A, BREWER R E, MARKOVIC M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]. Nature, 2019, 572(7769): 392-396. doi: 10.1038/s41586-019-1456-0
    [9]
    PEI Z, ZHU G, HUO X, et al. CD24 promotes the proliferation and inhibits the apoptosis of cervical cancer cells in vitro[J]. Oncol Rep, 2016, 35(3): 1593-1601. doi: 10.3892/or.2015.4521
    [10]
    ROSTOKER R, ABELSON S, GENKIN I, et al. CD24(+) cells fuel rapid tumor growth and display high metastatic capacity[J]. Breast Cancer Res, 2015, 17(1): 78. doi: 10.1186/s13058-015-0589-9
    [11]
    EYVAZI S, KAZEMI B, DASTMALCHI S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy[J]. Curr Cancer Drug Targets, 2018, 18(4): 328-336. doi: 10.2174/1570163814666170818125036
    [12]
    DENG X, APPLE S, ZHAO H, et al. CD24 Expression and differential resistance to chemotherapy in triple -negative breast cancer[J]. Oncotarget, 2017, 8(24): 38294-38308. doi: 10.18632/oncotarget.16203
    [13]
    KWON M J, HAN J, SEO J H, et al. CD24 Overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer[J]. PLoS One, 2015, 10(10): e0139112. doi: 10.1371/journal.pone.0139112
    [14]
    YANG X R, XU Y, YU B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery[J]. Clin Cancer Res, 2009, 15(17): 5518-5527. doi: 10.1158/1078-0432.CCR-09-0151
    [15]
    KRISTIANSEN G, SCHLVNS K, YONGWEI Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients[J]. Br J Cancer, 2003, 88(2): 231-236. doi: 10.1038/sj.bjc.6600702
    [16]
    LIU C, ZHENG S, SHEN H, et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence[J]. Oncol Lett, 2013, 6(1): 96-100. doi: 10.3892/ol.2013.1357
    [17]
    OVERDEVEST J B, KNUBEL K H, DUEX J E, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated[J]. Proc Natl Acad Sci U S A, 2012, 109(51): 3588-3596. doi: 10.1073/pnas.1113960109
    [18]
    LI Y, ZHOU J, ZHUO Q, et al. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression[J]. Cancer Manag Res, 2019, 11(4): 7123-7134. http://www.ncbi.nlm.nih.gov/pubmed/31534365
    [19]
    ABRAM C L, LOWELL C A. Shp1 function in myeloid cells[J]. J Leukoc Biol, 2017, 102(3): 657-675. doi: 10.1189/jlb.2MR0317-105R
    [20]
    KLEMBA A, PURZYCKA-OLEWIECKA J K, WCISO G, et al. Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance[J]. Contemp Oncol(Pozn), 2018, 22(1A): 48-55. http://www.termedia.pl/Journal/-77/pdf-32001-10?filename=Surface%20markers%20of%20cancer.pdf
    [21]
    NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
    [22]
    刘恒炜, 吕立群. 基于Oncomine数据库荟萃分析CD24在卵巢癌中的表达和临床意义[J]. 国际妇产科学杂志, 2019, 46(5): 580-584. doi: 10.3969/j.issn.1674-1870.2019.05.025
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (579) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return